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In Alzheimer’s disease (AD) Amyloid Beta (Aβ) is deposited in the form of extracellular plaques and previous 
studies have showed Aβ generation is cholesterol dependent. The use of statins in the prevention and treatment 
of AD is poorly explored. The aim of this work was, therefore, to perform a review of studies on the efficacy and 
safety of statins in the prevention as well as treatment of AD. 
Methods and Findings 
Medline and Cochrane Database of Systematic Reviews search was performed for original research articles 
published in English language in which participants received any type of statins for at least 6 months and 
evaluated for their cognitive changes. Selected articles were grouped into two, randomized controlled trials 
(RCTs) and observational studies, and meta-analyzed separately. Thirteen studies identified, 4 RCTs including 
1153 AD patients with trial period ranging from 26 to 72 weeks and 9 observational studies including 21,819 study 
participants with follow up period of up to 12 years. The 4 RCTs assessed change in Alzheimer’s Disease 
Assessment Scale- consisting of the cognitive subscale (ADAS-Cog) and when the results of each studies were 
combined there was no significant difference in ADAS-Cog between the statin and placebo group [Mean 
difference = -0.57, 95% CI, -1.39, 0.25, p=0.17]. Four of the 9 observational studies provided computed effect 
sizes in the form of Hazard ratio (HR) and common HR were computed and showed that statins had significant 
protective effect against AD [HR=0.69, 95% confidence interval (CI), 0.542, 0.882, p=0.003]. Three of the 9 
observational studies were also combined for their Odds ratio (OR) and they showed that statins were protective 
against AD [OR=0.447, 95% CI, 0.299, 0.668, p=000]. Treatment related adverse effects were similar between 
statin and placebo [OR=2.84, 95% CI, 0.41, 19.69, p=0.29]. 
Conclusion 
Though observational studies have shown statins’ protective effect against AD, there is insufficient evidence to 
recommend statins for the treatment of AD, as RCTs failed to show significant efficacy. Statins are generally well 
tolerated in AD. 
 
  




Alzheimer’s disease (AD) is an age-related neurodegenerative disease characterized by a progressive loss 
of memory associated with other cognitive sphere deficits interfering with social and occupational functioning 
(20). The global prevalence of AD was estimated at 26.55 million in 2006 (3). It has also been projected that 
worldwide prevalence will quadruple to 106.2 million, with 1 in 85 persons living with AD by the year 2050 
(3). AD is the commonest type of dementia encountered in older Patients (12). Dementia causes a significant 
financial burden to society, worldwide societal costs estimated at $315 billion in 2005 ($105 billion were for 
informal care) (32).There are a number of non-pharmacological and symptomatic pharmacological 
approaches to treat AD (9). None of these, however, can prevent, cure or stop the progression of the disease 
(9). 
The brain is the most cholesterol-rich human organ (26). Hypercholesterolemia is one of the modifiable risk 
factors for AD (1, 23). A central event in the development of AD is thought to be abnormal processing of the 
cell membrane-associated amyloid precursor protein (APP) followed by deposition of toxic Aβ protein in the 
form of amyloid plaques in the extracellular space of the neocortex (7, 25). High cholesterol level may 
increase the activity of the β- or γ-secretase enzymes that generate Aβ from APP, and may decrease the flux 
of APP through the nonamyloidogenic α-secretase pathway (26, 24). Once Aβ has been produced, the 
cholesterol level could also influence its aggregation state (24). Several studies in cell culture and animals 
have demonstrated that treatment with cholesterol lowering drugs, such as statins, reduces the production of 
Aβ (28, 5). It was, therefore, hypothesized that reduction of Aβ levels by statins may have neuro-protective 
effects in patients with AD (33, 27). 
Cholesterol forms an essential component of cell membranes, and has a crucial role in the development and 
maintenance of neuronal plasticity and function (26). Statin induced reduction in cholesterol concentration in 
the central nervous system may, therefore, cause neuro-cognitive deficits (18, 19, 13). The aim of this work 
was, therefore, to review the studies on the efficacy and safety of statins in the prevention and treatment of 
Alzheimer’s disease as well as the role of baseline cholesterol level, Apolipoprotein (APO) E genotyping, age 
and cognitive level on the treatment outcome. 
METHODS 
Inclusion Criteria 
 Randomized clinical trials (RCTs) in which study subjects were AD patients who received any type of 
statin for at least 6 months and cognitive changes were measured as outcomes using instruments 
such as ADAS-cog, Mini-Mental State Examination (MMSE) or other accepted cognitive measures. 
 Observational studies in which study subjects were either AD patients or subjects at risk for AD who 
received any type of statin for at least 6 months and data on incident AD cases were obtained or 
change in cognition measured by accepted cognitive measure. 
Search Strategy 
A comprehensive systematic search for published articles and conference proceedings was undertaken with 
the electronic database Medline via PubMed, and Cochrane Database of Systematic Reviews, using the 
following combination of medical subject headings (MesH) terms or key words: “Statins” and “Alzheimer’s 
Disease”. The search was restricted to articles published in English language irrespective of the study place. 
Reference lists of identified articles were also searched. 
Data Extraction 
The summary statistics required for each trial and each outcome for continuous data were the mean change 
from baseline, the standard error of the mean change, and the number of patients for each treatment group 
at each assessment. Where changes from baseline were not reported, the mean, standard deviation and the 
number of patients for each treatment group at each time point was extracted. For binary data (commonly 
found in observational studies) computed effect sizes (OR, HR) and their corresponding confidence limits 
were sought. 
  




Outcome measures that were extracted from non-randomized studies analyzed separately from the outcome 
measures extracted from randomized trials to avoid bias (11). 
Randomized trials  
The outcomes measured in clinical trials of AD and cognitive impairment often arise from ordinal rating 
scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 
10), the data were treated as continuous outcomes arising from a normal distribution (17). Summary 
statistics (sample size (n), mean and standard deviation) were required for each rating scale at each 
assessment time for each treatment group in each trial for change from baseline. The mean change and 
standard deviation were calculated from the available data. All data extracted were then entered into Review 
Manager (RevMan), Version 5.1 (The Cochrane Collaboration, Oxford, England) for analysis. The duration of 
the trials varied from 26-72 weeks. A separate meta-analysis was conducted for each period. Some trials 
may contribute data to more than one time period if multiple assessments have been done. 
Observational studies  
For binary outcomes, such as progression of AD, severity of AD, the odds ratio, relative risk, or hazard ratio 
were used to measure treatment effect. The Comprehensive Meta-Analysis software (Biostat, Englewood, 
NJ, USA), Version 2 was used for data analysis. 
In all cases the overall estimate from a fixed effect model is presented. Presence of heterogeneity was 
assessed using the Cochran Q statistic, and I2 statistic was also used to quantify the degree of statistical 
heterogeneity. If there was significant heterogeneity a random effects model will be presented. A 2-sided 
alpha error of less than 0.05 was considered to be statistically significant (P<0.05). Potential publication bias 
was assessed by visual inspection of the funnel plot produced by plotting the standard error against the 
mean difference of RCTs or log OR (HR) of observational studies. 
RESULTS 
The flow of studies through the review process is outlined in Figure 1. After a literature search and selection 
based on the inclusion criteria as described in the methods, a total of thirteen studies were identified that met 
inclusion criteria. All the thirteen studies (nine observational studies and four randomized controlled trials) 
were meta-analyzed separately. Tables 1 and 2 show RCTs and observational studies with their 
characteristics, respectively. 
Of the 4 RCTs, 2 were undertaken in USA, 1 in Germany and the remaining one was an international study 
in which patients were recruited from 10 different countries. Six of the 9 observational studies were 
undertaken in USA and the remaining in Canada, France and the Netherlands. Overall, 1153 study subjects 
were included in the 4 RCTs with trial period ranging from 26 to 72 weeks. In the 9 of observational studies, 
a total of 21,819 study participants were included with follow-up period of up to 12 years. 
Randomized Controlled Trials 
The four studies assessed change in ADAS-Cog and as study periods varied between 26 to 72 weeks, 
separate meta-analysis was conducted for each period (table 3). When the four studies were combined there 
was no significant difference in ADAS-Cog between the statin group and placebo group (p=0.17) (table 3). 
As the Simons 2002 study was conducted for 26 weeks, data from ADCLT 2006, LEADe 2010, Sano 2011 
and Simons 2002 at 6 months were combined and there was no significant difference in ADAS-Cog between 
the statin and placebo groups (p=0.49). As the ADCLT 2006 study was conducted for 12 months, data from 
ADCLT 2006, LEADe 2010 and Sano 2011 at 12 months were combined, and there was no significant 
difference in ADAS-Cog between the statin and placebo groups (p=0.60). Eighteen months data from LEADe 
2010 and Sano 2011 on Change in ADAS-Cog were also combined using random effect model (due to 
presence of heterogeneity), and there was no significant difference in ADAS-Cog between the statin and 
placebo groups (p=0.86). 
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Data on change in MMSE were also available from the four studies and separate meta-analysis was 
conducted for each period as it was done for ADAS-cog (table 4). No significant beneficial effect on MMSE 
was seen with statin treatment at any time. 
Three of the included RCTs (ADCLT 2006, LEADe 2010 and Sano 2011) also provided data on effect of 
statins on behavior using the instrument Neuropsychiatric Inventory Caregiver Distress Scale (NPI)) of AD 
patients. Data from these three studies were combined at the end point of each study and at 12 months 
(table 5). The effect was significantly different between groups only at 12 months (p=0.04) but not at end 
point (p=0.07) analysis. Eighteen months data from LEADe 2010 and Sano 2011 were also combined and 
found to be non significant (table 5). 
 
 
Fig. 1 Results of Pubmed and Cochrane collaboration database searches. 
 
Observational Studies 
One of the 9 included observational studies (i.e. Murali 2004) provided data using change in MMSE from 
baseline to follow-up period and the effect of statin on MMSE in statin users was not significant compared to 
statin non-users (p=0.429). Four of the remaining eight studies (Arvanitakis 2008, Higdon 2004, Li 2010, 
Rotterdam study 2009) provided computed effect sizes in the form of HR and the rest four (Hajjar 2002, 
Masse 2005, Peter 2005, Rockwood 2002) in the form of OR. The software used in the analysis 
(Comprehensive Meta-Analysis software) failed to accept data (OR, upper and lower limits) from Peter 2005 
and reported that its upper and lower limit log values were not symmetric. Common HR computed from the 
above mentioned four studies showed that statin use had significant protective effect against AD [HR=0.69, 
95% CI, 0.542, 0.882, p=0.003]. Computation of common OR from the above mentioned three studies also 
resulted in common OR=0.447, 95% CI, 0.299, 0.668, p=000, indicating that statin users had 0.447 times 
lower risk of AD compared to statin nonusers. 
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Baseline cholesterol level, APOE genotyping, age and cognitive level and treatment outcome: 
Data provided in ADCLT 2006 revealed that patients who improved on the ADAS-Cog had higher baseline 
cholesterol levels than those who deteriorated. (Mean change in ADAS-Cog score -2.14 ±1.20 in atorvastatin 
+ cholesterol >200mg/dl group, P=0.045 compared with placebo ≥200 mg/dl; 0.11±0.68 in atorvastatin + 
cholesterol <200mg/dl group). 
ADCLT 2006 also indicated that significant difference was seen in ADAS-Cog performance at 6 months 
between the atorvastatin and placebo groups in individuals with an APOE ε4 allele (p=0.012) but not 
between the groups comprised of subjects without an APOE ε4 allele (p=0.967). However, Arvanitakis 2008 
and Peter 2005 mentioned that there was no interaction of statins with APOE ε4 allele. Rotterdam study 
2009 provided data that the protective effect of statin use was similar for persons with an ApoE4 allele 
(adjusted HR 0.50; 95% CI 0.26 to 0.94) and for persons without an ApoE4 allele (adjusted HR 0.61; 95% CI 
0.32 to 1.18). Data from Higdon 2004 and Li 2010 revealed that, though overall interaction term for statin 
use-by-APOE ε4 was not significant, statin exposure was associated with a significantly lower risk of AD in 
the subjects < 80 years old at entry who had at least one APOE-ε4 allele and these data were combined and 
significant difference was seen [HR=0.31, 95% CI, 0.207, 0.739, p=0.004]. 
Among subjects treated with atorvastatin in ADCLT 2006, those who had improved on the ADAS-Cog at 6 
months had baseline MMSE scores 2 points higher than those who continued to deteriorate (21.93±0.85 
compared to 19.83±1.10, p<0.06). 
Data provided in Rockwood 2002 indicated that the OR for those younger than 80 years was 0.26 (95% CI, 
0.08, 0.88); while for those 80 years and older, it was 0.50 (95% CI, 0.13-1.88). The effect remains protective 
in those 80 years and older, the CI includes 1.0. Higdon 2004 and Li 2010 provided data on potential 
differential effect of statins in different age groups (<80 vs ≥80 years). Data from these two studies were 
combined and showed that statin use was associated with lower risk for probable AD in younger study 
subjects (HR=0.474, 95% CI, 0.298, 0.754, p=0.002), but not with study subjects ≥80 years (HR=1.464, 95% 
CI, 0.869, 2.467, p=0.152). 
Safety: 
LEADe 2010:  
There were 60 (19.1%) atorvastatin-treated and 69 (21.2%) placebo-treated patients who experienced 
serious adverse events (SAEs), 6 of whom in the atorvastatin group and 1 in the placebo group considered 
treatment related by the investigator or sponsor. There were 9 deaths (2.9%) in the atorvastatin group and 6 
(1.8%) in the placebo group. The SAEs for atorvastatin group were hepatitis, acute renal 
failure/rhabdomyolysis/pancreatitis, abdominal pain/ nausea/chest discomfort, transaminases elevation, liver 
disorder and gastrointestinal haemorrhage. 
Simons 2002:  
1 patient had muscle pain without elevation of creatine kinase, 1 patient was withdrawn because creatine 
kinase was elevated. No adverse effects were reported in the placebo group. 
Sano 2011:  
The groups did not differ in the number of subjects with SAEs (placebo group: 54/202 [26.7%]; treatment 
group: 56/204 [27.5%]; p = 0.91), the number of subjects with serious adverse events requiring 
hospitalization (placebo group: 46/202 [22.7%], active treatment group: 53/ 204 [25.9%]; p = 0.52), and the 
number of deaths (placebo group: 9/202 [4.5%], active group: 5/204 [2.5%]; p = 0.29). The most commonly 
occurring adverse events were falls, agitation, and anxiety. 
Data from LEADe 2010, Sano 2011 and Simons 2002 on treatment related adverse events requiring 
treatment discontinuation were combined and no significant difference between statin and placebo groups 
was seen [OR=2.84, 95% CI, 0.41, 19.69, p=0.29]. 




In this systematic review and meta-analysis, both randomized controlled trials comparing statins use in the 
treatment of AD with matching placebo, and observational studies comparing statin users associated risk for 
AD (or cognitive decline) with matching non-users were reviewed and analyzed separately. Including non-
randomized studies in reviews can be used to provide evidence of effects (benefit or harm) that cannot be 
adequately answered by reviews of randomized trials (11). To be included in the review, duration of the 
studies were expected to be at least six months. Six month was chosen as this was felt to be the minimum 
length of time required to be on treatment to allow a disease-modifying effect and before any cognitive 
benefit could be attained (17). 
This review provides inconsistent evidence between RCTs and observational studies. Mean change in 
ADAS-Cog and MMSE from baseline were an outcome in the four of the RCTs and there was no significant 
difference between the statin and the placebo groups. Mean change in NPI from baseline was also an 
outcome in the three of the included RCTs, i.e., ADCLT 2006, LEADe 2010 and Sano 2011, and significant 
difference between the statin and the placebo groups was seen only at 12 months study period, not at end 
points. These indicated that statins were not efficacious in the treatment of AD. A previous systematic review 
of RCTs assessed treatment of dementia or AD by statins (17). This was published before the Sano 2011 
results were available. Three studies were identified ADCLT 2005, LEADe 2010 and Simons 2002 as 
identified in this review, and there was no statistically significant treatment effect of statins on AD which is in 
agreement with the present review. While, common effect sizes computed from observational studies 
(common HR and OR) indicated that statins had strong protective effect against AD, though one of the 
studies (Murali 2004) failed to show significant protective effect. But the weight of Murali 2004 in the review 
of observational studies was very small (compared only 11 statin users with 22 statin non-users). 
There was evidence from ADCLT 2006 that greater cognitive effect from the statin (atorvastatin) was seen in 
patients with higher cholesterol and higher MMSE at baseline. ADCLT 2006 and combined results from two 
of the observational studies (Higdon 2004 and Li 2010) provided evidence that greater cognitive and 
protective effects were seen in participants harboring an APOE ε4 allele. There was also evidence from 
observational studies that better protective effect against AD from statins was seen in those participants 
whose baseline age was younger than 80 years. 
The statins were well tolerated and incidence of adverse effects was low. The statin group did not have a 
significantly higher rate of adverse effects requiring discontinuation of treatment when the data from the three 
of the RCTs, i.e., LEADe 2010, Sano 2011 and Simons 2002, were combined. There was no evidence that 
statins were detrimental to cognition. 
The main strength of this review was inclusion of observational studies and their separate analysis to provide 
evidence on association of statin use with AD which was not elucidated in the review of RCTs only. 
Publication bias is a potential limitation when carrying out a review. This source of bias has been addressed 
by using funnel plot, and there was no evidence of publication bias as assessed by visual inspection of the 
funnel plot produced by plotting the standard error against the mean difference of RCTs or log OR (HR) of 
observational studies. 
In summary, observational studies have shown that statins have strong protective effect against AD, 
whereas statins use in RCTs showed no significant effect on AD. This implies that there is insufficient 
evidence to recommend statins for the treatment of AD, as the level of evidence from RCTs outweighs than 
from observational studies. Negative clinical outcomes from RCTs accompanied by promising positive 
outcomes from observational studies signal a need for development of better randomized controlled study 
designs. Available RCTs designed to be run for shorter study periods than observational studies and that 
may affect the outcomes. 
From ADCLT 2006 there was some evidence that atorvastatin treatment was more beneficial at six months 
in AD patients with higher MMSE and higher cholesterol levels at baseline. There was also evidence from 
ADCLT 2006 and observational studies that statin treatment was more beneficial in study participants 
harboring an APOE-ε4 allele. And observational studies also suggested that statin use was associated with 
lower risk for probable AD in younger study subjects (<80 years), but not with study subjects ≥80 years. 
From the present study, we recommend to use large scale RCTs to further assess the impact of treatment at 
an earlier stage of the disease process, effect of age, effect of APO E ε-4 allele and effect of baseline 
cholesterol level. 
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Table 1: Characteristics of included RCTs 
Study ID 
ADCLT 2006 (30, 
31) 
LEADe 2010 (6) Sano 2011 (22) Simons 2002 (29) 
Method RCT RCT, multicentre RCT, multicenter RCT 
Participants 
63 AD patients (32 
atorvastatin, 31 










317=placebo with MITT), 
Age 50-90 years, Total 
cholesterol, mean (SD), 
mg/dl: Atorvastatin= 
225.1 (33.7), Placebo= 
223.1 (33.3) 
406 AD patients 
(204 in the 
simvastatin, 202 
placebo), age > 




placebo (208.8 ± 
28.6), simvastatin 
(215.0 ± 32.5). 
44 AD Patients (20 
placebo, 24 simvastatin) 
















mg, study- 40 
mg/day. Control: 
identical placebo 
Intrvention: 40 mg for 4 
weeks then, 80mg 
simvastatin for the rest 22 





Cog, MMSE, NPI. 
Change in ADAS-Cog, 
NPI, MMSE 
Change in ADAS-
Cog, NPI, MMSE 




single site in USA, 
1 year 
Patients recruited from 
Australia, Austria, 
Canada, Denmark, 
Germany, South Africa, 
Spain, Sweden, UK and 
USA. 72 weeks trial 
period followed by 8 
week atorvastatin 
withdrawal phase 
45 sites in USA, 
Initiation 6 weeks 
plus study 18 
months 
Germany, 26 weeks 




Table 2: Characteristics of included observational studies 











929 older Catholic 
clergy, mean baseline: 
Age 74.9 yrs, statin 
users= 119 (12.8%), 
statin nonusers= 810 
(87.2%) 
Incident AD HR 
USA, ≤12 
years. 
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655 patients (113 statin 
users, 542 non-statin 
users), mean baseline 
age 78.7±0.3 years. 







2,356 cognitively intact 
persons, mean baseline 
age 75.1 ± 6.1years 
Incident AD HR 
USA, 3.9 ±2.8 
years 
Li 2010 (15) 
Community based-
Cohort -every 2 years 
follow-up 
3,099 participants (711 
statin users, 2,388 statin 
nonusers), mean 
baseline age (Statin 
users =74.2 ± 5.5 Statin 
nonusers =75.8 ±6.4) 




342 AD patients, Mean 
(SD) age in years: 70 
(7.4) at onset, 73.5 (7.3) 
at first visit, and 76.5 
(7.5) at the end of the 
follow up (range 42 to 
99). 
Cognitive 










elderly subjects (35 LLA 
users, 211 LLA 
nonusers), mean 
baseline age LLA users 











4895 participants aged 
≥65years, 4572 statin 
nonusers, 292 statin 
users Mean age (SD) in 
years: Nonusers= 75.7 












survey of Canada 
Study of Health and 
Aging (CSHA) 
Participants (Canadians 
aged ≥65 years) from 
CSHA. Controls (n=823), 
Cases (n=326) , Statin 
users (n= 57), nonusers 
(n = 2234) 
Association 










6992 (age ≥55 years) 
participants, mean 
baseline age (SD) in 
years= 69.4 (9.1) 




LLA= Lipid lowering agents 
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Table 3. Change in cognition measured by change in ADAS-cog (error score). Mean difference 
obtained by subtracting weighted mean change in ADAS-cog score of placebo group from weighted 
mean change in ADAS-cog score of statin group. 
Study period Mean difference [95% CI] P-Value 
From baseline to end points -0.57 [-1.39, 0.25] 0.17 
From baseline to 6 months -0.24[-0.93, 0.45] 0.49 
From baseline to 12 months -0.24[-1.15, 0.66] 0.60 
From baseline to 18 months 0.19[-1.93, 2.31] 0.86 
 
Table 4. Change in cognition measured by change in MMSE (correct score). Mean difference obtained 
by subtracting weighted mean change in MMSE score of placebo group from weighted mean change 
in MMSE score of statin group. 
Study period Mean difference [95% CI] P-Value 
From baseline to end points 0.57[-0.36, 1.50] 0.23 
From baseline to 6 months 0.21[-0.15, 0.58] 0.25 
From baseline to 12 months 0.27[-0.18, 0.73] 0.24 
From baseline to 18 months 0.06[-0.92, 1.04] 0.90 
 
Table 5. Effect of statin on behavior, measured in NPI change (error score). Mean difference obtained 
by subtracting weighted mean change in NPI score of placebo group from weighted mean change in 
NPI score of statin group. 
Study period Mean difference [95% CI] P-Value 
From baseline to end points -0.77[-1.59, 0.06] 0.07 
From baseline to 12 months -1.03[-2.03, -0.04] 0.04* 
From baseline to 18 months -0.76[-2.01, 0.49] 0.23 
*- Significant difference between statin and placebo groups 
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